We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breast Cancer Diagnosis Uses Spatial Light Interference Microscopy

By LabMedica International staff writers
Posted on 16 Sep 2015
The standard practice in histopathology of breast cancers is to examine a hematoxylin and eosin (H&E) stained tissue biopsy under a microscope to diagnose whether a lesion is benign or malignant.

A new optical method called Spatial Light Interference Microscopy (SLIM) has been used to quickly and accurately determine whether breast tissue lesions are cancerous, as this quantitative, label-free, and high-throughput diagnosis method is highly advantageous.

Scientists at the University of Illinois (Urbana, IL, USA) used the breast tissue biopsies of 400 different patients, and selected two parallel, adjacent sections from each biopsy. More...
One was stained and the other left unstained. The unstained samples were analyzed using a SLIM module attached to a commercial phase contrast microscope to generate interferograms, which are photographic images derived from data based on how the tissue refracts light.

Four interferograms were used to produce one quantitative image showing areas with different refractive properties in different colors. The boundary between tumors and the cells around them were clearly delineated, making it possible to assess whether the tumors were malignant or benign. As a first step toward quantitative diagnosis based on SLIM, the team carried out a qualitative evaluation of our label-free images. These images were shown to two pathologists who classified each case as either benign or malignant. This diagnosis was then compared against the diagnosis of the two pathologists on corresponding H&E stained tissue images and the number of agreements were counted.

The agreement between SLIM and H&E based diagnosis was 88% for the first pathologist and 87% for the second. The results demonstrate the potential and promise of SLIM for quantitative, label-free, and high-throughput diagnosis. YongKeun Park, PhD, a professor at Korean Advanced Institute of Science and Technology (Daejeon, Republic of Korea) and a guest editor of the of the special section on Quantitative Phase Imaging in Biomedicine in which the study appears said, “Conventional methods for diagnosis of breast cancer have several limitations, including observer discrepancy.” The study was published on August 20, 2015, in the Journal of Biomedical Optics.

Related Links:

University of Illinois 
Korean Advanced Institute of Science and Technology



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
POC Immunoassay Analyzer
Procise DX
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.